

Ain Shams University Faculty of postgraduate childhood studies

Prognostic Clinical and Laboratory Parameters in Children with primary Immune Thrombocytopenic Purpura

Thesis

Submitted for Fulfillment of PHD in Childhood studies (Child Health and Nutrition) Medical Studies Department

By

Amira Ahmed Nazim

M.Sc. Pediatrics, Mansoura University

Supervisors

Prof. Dr. Randa Kamal Abdel Raouf

Professor of Pediatrics

Department of medical studies

Faculty of postgraduate childhood studies

Ain Shams University

Dr. Ahmad Darwish Mohamad

Lecturer of Pediatrics

Faculty of Medicine - Mansoura University


Dr. Ziyad Mohamed Essam Eldin Tawhid

Ass.Prof. of Clinical Pathology

Faculty of Medicine - Mansoura University

Ain Shams University

2018



LIST OF CONTENTS

List of Abbreviations	I
List of Tables	Ш
List of Figures	IV
Introduction	1
Aim of work	4
Review of Literature	
• Immune Thrombocytopenia	5
• Prognosis Of ITP	27
• Treatment Of ITP	35
Subjects and Methods	52
Results	60
Discussion	114
Summary and Conclusions	123
Recommendations	125
References	126
Appendix	152
الملخص العربي	1

List of Abbreviations

AIEOP	Associazione Italiana di Ematologia e Oncologia Pediatrica	
ALC	Absolute lymphocyte count	
ALPS	Autoimmune lymphoproliferative syndrome	
ANA	Anti-nuclear antibody	
ANOVA	Analysis of variance	
Bregs	Regulatory B cells	
CagA	Cytotoxin associated gene A	
СВС	Complete Blood Count	
CVID	Common variable immunodeficiency	
DTap	Diphtheria Tetanus Pertussis Vaccine	
EDTA	Ethylenediaminetetraacetic acid	
ELISA	Enzyme Linked Immunosorbent Assay	
FCIA	Flow Cytometric Immunobead assay	
Hb	Hemoglobin	
HCV	Hepatitis C virus	
HIV	Human immunodeficiency virus	
ICIS	Intercontinental cooperative ITP study group	

ITAMs	Immunoreceptor tyrosine-based activation motifs
ITIM	Immunoreceptor tyrosine-based inhibitory motif
ITP	Immune thrombocytopenia
IVIG	Intravenous immunoglobulin
IWG	International Working Group
JAK	Janus kinase
KIR	Killer cell immunoglobulin-like receptor
LS	Laparoscopic splenectomy
MAP	Mitogen-activated protein
MMR	Measles Mumps Rubella Vaccine
MPV	Mean platelet volume
OD	Optical densit
PARC-ITP	Pediatric and Adult Registry of Chronic ITP
RAISE	Randomized Placebo- Controlled ITP Study with Eltrombopag
RITP	Refractory idiopathic thrombocytopenic purpura
RPM	Revolutions per minute
SDMP	Standard-Dose Methylprednisolone

SPSS	Statistical package for social science
STAT	Signal transducers and activators of transcription
TLC	Total leukocyte count
Tregs	Regulatory T cells
WASP	Wiskott-Aldrich syndrome protein
WBCs	White blood cell

List of Tables

No	Title	Page		
Review of Literature				
1	Definition of bleeding manifestations according to clinical examination	22		
2	Causes of secondary thrombocytopenia	26		
3	First-line therapy in children with ITP	50		
4	Treatment options in children with persistent or chronic ITP	51		
Results				
1	Descriptive data of demographic features of the studied cases	60		
2	Descriptive data of the clinical findings of patients	63		
3	Descriptive data of laboratory findings of patients	66		
4	Descriptive data of different lines of treatment had been taken by the studied cases	69		
5	Comparison between demographic data of group Ia & groupIb patient	70		
6	Comparing the clinical findings of patients of both groups	74		
7	Comparing the laboratory findings of patients of both groups	80		
8	Comparing different lines of treatment had been taken by the patient and the course of the disease	85		
9	Comparing the laboratory findings of the patient and control	87		
10	Comparing the laboratory findings of the patient and control	93		

List of Figures

No	Title	Page	
Review of Literature			
1	Immune thrombocytopenia pathogenesis	7	
2	Clinical Features of Immune Thrombocytopenic Purpura. (petechiae and purpura)	21	
3	Blood Film Examinations From Patients With Thrombocytopenia	24	
Results			
1	The percentage of male patients versus that of female patients $(n = 44)$	60	
2	The percentage of patients from rural area versus that of patients from urban area $(n = 44)$	62	
3	Age of incidence of ITP in the present study	62	
4	The percentage of ITP incidence in the four season $(n = 44)$	64	
5	Descriptive data of the clinical findings of patients	65	
6	Median of platelet count & antiglycoprotien antibodies in ITP cases of the present study	66	
7	Mean of MPV &WBC in ITP cases of the present study	67	
8	platelet count in ITP cases after 1year	68	
9	The relation between the age of the patient and the course of the disease	71	
10	The relation between the sex of the patient and the course of the disease	72	
11	The relation between the residence of the patient and the course of the disease	73	

12	The relation between the season of the occurrence and the course of the disease	75
13	The relation between the onset of incidence and the course of the disease	76
14	The relation between the presence of viral infection and the course of the disease	77
15	The relation between the presence of cutaneous bleeding and the course of the disease	78
16	The relation between the presence of mucosal bleeding and the course of the disease	79
17	Comparison between MPV and WBC.in both groups	81
18	The relation between the initial platelet count of the patient and the course of the disease	82
19	The relation between the antiglycoprotien antibodies and the course of the disease	83
20	The platelet count of the patient after 1 year	84
21	Comparison between lines of treatment had been taken by the studied cases	86
22	Comparison between MPV in patients &control	88
23	Comparison between WBC in patients &control	89
24	Comparing the antiglycoprotien antibodies between the control and patient group	90
25	Comparing the platelet count between the control and patient group	91
26	Comparing the platelet count between the control and patient group after one year	92
27	Comparison between MPV in patients &control	94
28	Comparison between WBC in patients &control	95
29	Comparing the antiglycoprotien antibodies between the control and patients groups	96

30	Comparing the initial platelet count between the control and patients groups	97
31	Comparing the platelet count of the patients groups after one year and the control	98
32	Correlation between WBC and the antiglycoprotien antibodies for the three groups of the study	100
33	Correlation between WBC and the age for the three groups of the study	101
34	Correlation between PLT and the antiglycoprotien antibodies for the three groups of the study	102
35	Correlation between WBC and MPV for the three groups of the study	103
36	Correlation between MPV and the age for the three groups of the study	104
37	Correlation between PLT and AB for the three groups of the study	105
38	Correlation between WBC and PLT for the three groups of the study	106
39	Correlation between MPV and AB for the three groups of the study	107
40	Correlation between MPV and PLT for the three groups of the study	108
41	Correlation between age in `years and AB for the three groups of the study	109
42	Correlation between MPV and PLT after 1 year for the three groups of the study	110
43	Correlation between WBC and PLT after 1 year for the three groups of the study	111
44	Correlation between PLT after 1 year and AB for the three groups of the study	112
45	Correlation between age in `years and PLT after 1 year for the three groups of the study	113



INTRODUCTION

The term ITP refers to "immune thrombocytopenic purpura," "idiopathic thrombocytopenic purpura," and, most recently, "immune thrombocytopenia" (*Ruggeri et al., 2008*).

ITP is an autoimmune disease characterized by a decreased platelet count (less than 100×10^9 /L) due to destruction of antibody-sensitized platelets in the reticuloendothelial system (RES) (*Blanchette and Bolton-Maggs*, 2010, *Lanzkowsky*, 2011).

Primary ITP is isolated thrombocytopenia (platelet count $< 100 \times 10^9$ /L) in the absence of disorders or other causes that may be presented with thrombocytopenia (*Semple et al., 2010*).

Secondary ITP is any form of immune disease causing thrombocytopenia except primary; such as systemic lupus erythematosus (SLE), infection with hepatitis C or lymphoproliferative disease (*Lanzkowsky*, 2011).

The term "newly-diagnosed ITP" now replaces the old term "acute ITP", which is any ITP diagnosed within the preceding 3 months. Persistent ITP refers to immune thrombocytopenia of 3-12 months duration, while immune thrombocytopenia more than 12 months duration is refer to chronic ITP (Semple et al., 2010, Lanzkowsky, 2011).

Primary ITP is a diagnosis of exclusion by carefully ruling out causes of pseudo thrombocytopenia, secondary ITP, and inherited ITP. Obtaining an accurate history combined with a complete blood count is the first and most important step. The diagnosis of ITP is based up on the following criteria:

- Acute onset of bruising and petechiae in an otherwise healthy child-often with a recent history of viral infection.
- Platelet count $<100,000\times10^9/L$ (often $<20,000\times10^9/L$).
- Otherwise normal complete blood count (CBC) with differential white count, and reticulocyte count.
- No abnormalities on the peripheral blood smear after review by an experienced practitioner. In particular, there should be no evidence of hemolysis or of blast cells.
- No clinically apparent associated conditions that may cause thrombocytopenia, after a thorough history and physical examination. Findings that suggest a diagnosis other than ITP include enlargement of lymph nodes, liver, spleen or systemic symptoms (e.g., fever, anorexia, bone or joint pain, or weight loss) (Rodeghiero et al., 2009).

The majority of children with acute ITP will require only advice, support and repeat CBC 10 days after diagnosis to ensure that there is no generalized marrow disorder. Further monitoring of the CBC is not required unless a change in the child's condition takes place to suggest that remission has occurred, or that deterioration has taken place.

Any of the following may be used in a special setting if it is thought that the clinical condition requires that the platelet count should be raised :(prednisone, intravenous immunoglobulin, IV anti-D immunoglobulin).

The majority of children achieve spontaneous remission and do not suffer major bleeding complications despite a platelet count $<10 \times 10^9/L$.

The expectant 'watch and wait' policy of management is recommended for such patients. In the absence of 'wet bleeding', the child does not require hospitalization. The frequency of follow up blood counts should be limited to every 1-2 weeks initially and lesser thereafter, in order to avoid unnecessary hospital visits and anxiety (*Imbach et al.*, 2006).

Anti-D may be considered for first-line therapy in Rh + non splenectomized children (*Neunert et al.*, 2011).

Definition of study concepts:

ITP: it is an autoimmune disorder characterized by immunologic destruction of otherwise normal platelets most commonly occurring in response to an unknown stimulus.

Primary ITP: is a platelet count less than 100 x 10⁹/L in the absence of other causes or disorders that may be associated with thrombocytopenia.

Mean platelet volume (MPV): is a measure of platelet size.

A viral prodroma: is defined as a documented history of upper respiratory tract illness (URI), gastrointestinal (GI) symptoms, or skin exanthema within 4 weeks of diagnosis of ITP.

Pseudo thrombocytopenia: is the result of platelets clumping in the presence of ethylenediaminetetraacetic acid (EDTA).